Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use of HPV vaccines. GARDASIL 9 has been added to the routine recommendations for vaccination of 11- and 12- year-old females and males. The vaccination series can be started at age nine. Language: English Contact: Media:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913Investor:Justin Holko, 908-740-1879Amy Klug, 908-740-1898 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/83723ae8-8ced-4eba-af3f-282064c0e25f_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-83723ae8-8ced-4eba-af3f-282064...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News Source Type: news